The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value - Summary - MDSpire
Advertisement
The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value
To investigate the diagnostic efficacy of combining Prostate Health Index (PHI) with multiparametric magnetic resonance imaging (mpMRI) in patients with varying PSA levels, particularly focusing on the clinical implications of these variations.
Key Findings:
Out of 120 patients, 48 (40.0%) were confirmed to have prostate cancer (PCa), with 37 (30.8%) classified as clinically significant PCa (csPCa). Among patients with negative MRI findings (PI-RADS < 3), 9.1% were diagnosed with PCa. The combination of PHI and mpMRI improved detection rates compared to using either method alone, highlighting its clinical significance.
Interpretation:
The combination of PHI and mpMRI enhances the diagnostic accuracy for prostate cancer, particularly in patients with PSA levels between 4-10 ng/ml, suggesting a potential shift in clinical practice.
Limitations:
The study's findings may not be generalizable due to the limited geographical scope and sample size. The reliance on histopathological confirmation may introduce bias based on biopsy sampling techniques, which should be acknowledged.
Conclusion:
Combining PHI with mpMRI offers a promising approach to improve prostate cancer diagnosis and reduce unnecessary biopsies, particularly in patients with intermediate PSA levels, potentially transforming patient management.
